Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer [Financial Post (Toronto, Ontario, Canada)]
Genenta Science S.p.A. - American Depositary Shares (GNTA)
Company Research
Source: Financial Post
Glioblastoma study achieves milestone with successful dose escalation, setting stage for Phase 2 MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), marking a significant expansion of the potential applications for Genenta's flagship product, Temferon™. This approval by AIFA is in line with the standards that are harmonized across European regulatory frameworks established by the European Medicines Agency (EMA). From the CEO's Desk: Pierluigi Paracchi , CEO and Co-founder of Genenta, stated: “This approval to initiate a Phase 1 trial in metastatic renal cell carcinoma marks another significant milestone for Genenta, leverages the encouraging results from treating Glioblastoma Multiforme (GBM), and underscores our platform's pote
Show less
Read more
Impact Snapshot
Event Time:
GNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNTA alerts
High impacting Genenta Science S.p.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GNTA
News
- Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective" [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”GlobeNewswire
- Genenta Science S.p.A.'s (NASDAQ:GNTA) market cap rose US$46m last week; individual investors who hold 55% profited and so did insiders [Yahoo! Finance]Yahoo! Finance
- Genenta Science S.p.A. (NASDAQ: GNTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
- Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell CancerGlobeNewswire
GNTA
Analyst Actions
- 10/2/24 - HC Wainwright
GNTA
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 424B5
- 12/13/24 - Form 6-K
- GNTA's page on the SEC website